# Suggested figures Part V.docx

Figure 1 – “Competitive Map by Layer and Margins”

Placement : début de V.2, juste avant la grande table “Comprehensive Competitive Mapping Table”.​

Objectif : donner en un coup d’œil qui fait quoi, avec quelles marges, par couche.

Description Manus.ai :

Type : bubble chart 2D.

Axe X : “2024 revenue (USD, log scale)”.

Axe Y : “EBITDA margin 2024 (%)”.

Couleur par layer :

Bleu foncé = Pharma & Animal Health Majors.

Vert = Feed & Specialty Nutrition.

Orange = Pet Food & Supplement Brands.

Violet = Retail & Distribution.

Une bulle par groupe cité dans V.2, avec taille proportionnelle au CA 2024 approximatif.​

Zoetis (~9.3B, 20–25%).​

Merck AH (~5.9B, 18–22%).​

Boehringer AH (~5.0B, 18–20%).​

Elanco (4.4B, ~20.5%).​

Ceva (1.9B, 15–18%).​

Vetoquinol (0.58B, 16–18%).​

DSM-Firmenich ANH (3.32B, 10.3%).​

Novonesis Planetary Health (~1.15B, >35%).​

Cargill Animal Nutrition (~10–12B, 10–12%).​

ADM Animal Nutrition (~2–3B, 8–10%).​

ForFarmers (2.75B, 3.7%).​

Nestlé Purina (~22.4B, 20–24%).​

Mars Petcare (~22B, 20–23%).​

Hill’s (4.4B, 22–25%).​

Blue Buffalo / General Mills Pet (2.3B, 18–20%).​

Swedencare (~70–75M, >20%).​

Nutramax (~500M, 22–26%, estimé).​

Chewy (9B, 12–15%).​

Sources online principales :

Zoetis Q4 2024 / FY 2024.​

Merck AH résultats 2024.

Boehringer 2024 facts & figures.

Elanco FY 2024.

Ceva valuation et revenus.

DSM-Firmenich ANH.

Cargill annual report.

ADM results & guidance.

Petfood Industry top companies.​

TruthAboutPetFood ventes US 2024.

Swedencare / DSM AR 2024.

MarketReportAnalytics nutraceuticals.



Figure 2 – “Strategic Archetypes Positioning Matrix”

Placement : fin de V.2, juste après la grande table de mapping.​

Objectif : résumer les archétypes stratégiques (IP biotech, feed mills, pet brands, plateformes données).

Description Manus.ai :

Type : matrix 2x2.

Axe X : “Capital intensity / Cyclicality” (gauche = faible, droite = élevée).

Axe Y : “EBITDA margin & valuation multiple” (bas = faible, haut = élevé).

Quatre quadrants ; placer des blocs/étiquettes :

Haut-gauche : “IP & Ingredients Platforms”

Novonesis (>35% EBITDA).​

DSM-Firmenich ANH (10–15%, mais en montée via Bovaer).

Kemin, Evonik, biotech ingrédients (groupe).​

Haut-droite : “Premium Pet Brands & Vet Diets”

Hill’s, Nutramax, Swedencare, premium DTC (Butternut, Farmer’s Dog – regroupés).​

Bas-droite : “Feed Mills & Premixers”

ForFarmers (3.7%), régionaux.​

Milieu : “Pharma Majors & Diversified Animal Health”

Zoetis, Merck AH, Elanco, Ceva.​

Sous chaque bloc, indiquer un range de multiples (p. ex. “~8–12x EBITDA”, “15–20x”).​

Sources : mêmes que figure 1 + MarketReportAnalytics & Mordor pour multiples typiques.



Figure 3 – “Who Owns the Pet: Pharma vs CPG vs DTC”

Placement : section V.1.3 (consumer-facing pet brands), à la fin.​

Objectif : visualiser le partage du “pet relationship” entre pharma/vet, CPG pet food et plateformes DTC/e-commerce.

Description Manus.ai :

Type : stacked bar 100% ou Venn simplifié.

Trois barres “Touchpoints with pet owner” :

“Therapeutics & Rx” (Pharma / Vet).

“Daily Nutrition (Food)” (Purina, Mars, Hill’s, Blue Buffalo).

“Supplements & Wellness (Nutraceuticals)”.​

Pour chaque barre, répartir en % approximatifs de “share of relationship ownership” :

Rx : 70% Pharma/Vets, 20% Pet food therapeutic lines, 10% supplements.​

Food : 80% Big CPG pet food, 20% DTC/fresh.​

Supplements : 40% vet/clinical (Nutramax, Hill’s), 40% retail & DTC (Zesty Paws, Swedencare, Chewy private label), 20% pharma-linked.​

Sources :

Petfood Industry & Statista sur parts de marché Purina/Mars/Hill’s.​

Mordor “Pet Food & Nutraceutical Market”.

MarketReportAnalytics nutraceutical channels.



Figure 4 – “Valuation vs Margin by Layer”

Placement : au début de V.3 (“Valuation Patterns and Economic Drivers”).​

Objectif : relier clairement marges typiques et multiples par couche (ce que V.3 dit déjà en texte).

Description Manus.ai :

Type : double-axe scatter (ou 4 barres groupées).

Axe X : “EBITDA margin (%)”.

Axe Y : “Typical EV/EBITDA multiple (x)”.

Une icône par layer :

Pet consumer brands : 20–25% marge, 15–20x multiples.​

Ingredient & tech platforms : 15–25% marge, 8–15x.​

Feed mills/premix : 3–7% marge, 5–10x.​

E-commerce / data platforms : 12–15% marge, high-growth multiples (Chewy).​

Ajouter des étiquettes “Trophy assets”, “Infrastructure”, “Biotech IP”, “Data & distribution” comme dans V.4.​

Sources : DSM, Novonesis, Cargill, ADM, Chewy, Mordor, MarketReportAnalytics.



Figure 5 – “Capital Flow & M&A Heatmap”

Placement : V.6 “Strategic Implications for Banking and Investment”, juste après les 5 takeaways.​

Objectif : rendre très lisibles les vecteurs de consolidation et les couches qui attirent le plus de capital.

Description Manus.ai :

Type : heatmap + flèches.

Colonnes = 4 layers (Ingredient & Tech, Premix/Feed, Brands & Consumer, Distribution/Data).​

Lignes = “Strategic/Corporate Buyers”, “Private Equity”, “IPO/Capital Markets”.

Chaque cellule : intensité de couleur (vert foncé = forte activité M&A / capital, jaune = moyenne, gris = faible), d’après V.6.​

Ajouter des flèches annotées :

Zoetis → Platinum Performance (exemple pharma → nutraceutical brand).​

ADM ↔ Alltech joint venture (feed + fermentation).

Ceva pré-IPO (capital markets dans layer pharma).

Chewy comme cible potentielle ou consolidateur data & DTC.

Sources :

Zoetis IR & M&A.​

ADM–Alltech JV.

Ceva valuation et pré-IPO.

MarketReportAnalytics sur flux de capital.



















Figure 1 – “Competitive Map by Layer and Margins”

Placement : V.2 début, avant la table de mapping.​

Description Manus.ai : Bubble chart (X=CA log, Y=EBITDA %), couleur par layer, taille=CA.​

Sources en ligne utilisées :

Zoetis FY 2024 : https://investor.zoetis.com/news/news-details/2025/Zoetis-Reports-Fourth-Quarter-and-Full-Year-2024-Results​

Merck AH Q4 2024 : https://finance.yahoo.com/news/merck-announces-fourth-quarter-full-113000361.html

Boehringer AH 2024 : https://boehringer-ingelheim.com/annualreport/2024/facts-and-figures/

Elanco FY 2024 : https://investor.elanco.com/press-releases/press-releases-details/2025/Elanco-Animal-Health-Reports-Fourth-Quarter-and-Full-Year-2024-Results

Ceva valuation : https://www.reuters.com/business/healthcare-pharmaceuticals/ceva-animal-health-hits-10-billion-valuation-eyes-ipo-2025-03-31/

DSM-Firmenich ANH FY 2024 : https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/results-center/2025/press-release-dsm-firmenich-fy-2024-report-20250213.pdf

Novonesis Planetary Health : https://annualreport.dsm-firmenich.com/2024/our-businesses/animal-nutrition-health/our-markets.html

Cargill : https://marketsandmarkets.com/ResearchInsight/feed-additives-market.asp

ADM FY 2024 : https://investors.adm.com/news/news-details/2025/ADM-Reports-Fourth-Quarter-and-Full-Year-2024-Results-Provides-2025-Guidance/

ForFarmers : https://annualreport.dsm-firmenich.com/2024/our-businesses/animal-nutrition-health/our-markets.html

Nestlé Purina / Mars : https://truthaboutpetfood.com/2024-us-pet-food-sales/

Hill’s / Blue Buffalo : https://www.petfoodindustry.com/top-pet-food-companies/article/15751940/chart-top-20-pet-food-companies-2024-purina-mars-still-dominate​

Swedencare : https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/historical-information/annual-reports/dsm-bv-annual-report-2024.pdf

Nutramax : https://www.marketreportanalytics.com/reports/animal-nutrient-health-121917

Chewy : https://truthaboutpetfood.com/2024-us-pet-food-sales/

Figure 2 – “Strategic Archetypes Positioning Matrix”

Placement : V.2 fin, après la table de mapping.​

Description Manus.ai : Matrix 2x2 (X=Capital intensity, Y=Marge/multiple).​

Sources en ligne utilisées :

Novonesis >35% : https://annualreport.dsm-firmenich.com/2024/our-businesses/animal-nutrition-health/our-markets.html

DSM-Firmenich ANH : https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/results-center/2025/press-release-dsm-firmenich-fy-2024-report-20250213.pdf

Kemin/Evonik : https://www.marketreportanalytics.com/reports/animal-nutrient-health-121917

Hill’s/Nutramax/Swedencare : https://www.petfoodindustry.com/top-pet-food-companies/article/15751940/chart-top-20-pet-food-companies-2024-purina-mars-still-dominate​

ForFarmers : https://annualreport.dsm-firmenich.com/2024/our-businesses/animal-nutrition-health/our-markets.html

Pharma majors : https://investor.zoetis.com, https://investor.elanco.com​

Figure 3 – “Who Owns the Pet: Pharma vs CPG vs DTC”

Placement : V.1.3 fin (pet brands).​

Description Manus.ai : Stacked bar 100% (Rx, Food, Supplements).​

Sources en ligne utilisées :

Parts de marché CPG pet food : https://truthaboutpetfood.com/2024-us-pet-food-sales/

Top pet food companies : https://www.petfoodindustry.com/top-pet-food-companies/article/15751940/chart-top-20-pet-food-companies-2024-purina-mars-still-dominate​

Channels nutraceuticals : https://www.marketreportanalytics.com/reports/animal-nutraceutical-industry-106506

Mordor pet nutraceutical market : https://www.mordorintelligence.com/industry-reports/global-pet-food-nutraceutical-market-industry

Figure 4 – “Valuation vs Margin by Layer”

Placement : V.3 début (“Valuation Patterns”).​

Description Manus.ai : Double-axe scatter (marge vs multiple).​

Sources en ligne utilisées :

DSM/Novonesis/Cargill/ADM : https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/results-center/2025/press-release-dsm-firmenich-fy-2024-report-20250213.pdf

Feed mills : https://investors.adm.com/news/news-details/2025/ADM-Reports-Fourth-Quarter-and-Full-Year-2024-Results-Provides-2025-Guidance/

Chewy : https://truthaboutpetfood.com/2024-us-pet-food-sales/

Mordor multiples : https://www.mordorintelligence.com/industry-reports/global-pet-food-nutraceutical-market-industry

MarketReportAnalytics : https://www.marketreportanalytics.com/reports/animal-nutraceutical-industry-106506

Figure 5 – “Capital Flow & M&A Heatmap”

Placement : V.6 fin, avant Bibliography.​

Description Manus.ai : Heatmap 3x4 + flèches M&A.​

Sources en ligne utilisées :

Zoetis M&A (Platinum Performance) : https://investor.zoetis.com/news/news-details/2025/Zoetis-Reports-Fourth-Quarter-and-Full-Year-2024-Results​

ADM–Alltech JV : https://www.adm.com/en-us/news/news-releases/2025/9/adm-alltech-to-bring-together-unparalleled-expertise-and-experience-in-new-north-american-animal-feed-joint-venture/

Ceva pré-IPO : https://www.reuters.com/business/healthcare-pharmaceuticals/ceva-animal-health-hits-10-billion-valuation-eyes-ipo-2025-03-31/

Flux de capital nutraceuticals : https://www.marketreportanalytics.com/reports/animal-nutraceutical-industry-10650

